| Clinical Diagnostics and Pathology Services | Routine, semi-specialized, specialized, and super-specialty diagnostic lab tests. | Extensive lab network, technological innovation (AI, NGS), strong brand trust, regulatory accreditations (ISO, NABL, CAP). | B2C patients, hospitals, corporates, government health programs, clinical research organizations (B2B & B2G). | Specialty and genomics tests, wellness diagnostic packages, digital consultation services. | 1221 | 92 | Revenue from patient test fees, hospital tie-ups, corporate contracts, and government tenders. | Fee-for-service with premium pricing on specialty and wellness packages; mix of direct sales and institutional contracts. | Increasing health awareness, rise in chronic diseases, specialty testing demand, expansion into new cities. | Metropolis Diagnostic Network, Core Diagnostics, Scientific Pathology |
| International Operations | Diagnostic lab and pathology services tailored to regional markets. | First-mover advantage and partnerships, leveraging Indian expertise and technology transfer. | Hospitals, clinics, and patients in overseas operations and partner countries. | Specialized testing and reference lab services. | 109 | 8 | Lab test service fees from international patients and institutional clients. | Fee-for-service model adjusted for local markets. | Expansion in African and Asian emerging markets, partnerships with local healthcare providers. | Metropolis Laboratories in Ghana, Kenya, Zambia, Mauritius, Sri Lanka |
